TaiGen
Overview
Milestones
Business Model
Steering Committee
Directors and Supervisors
Management
Pipline
Clinical Pipline
Preclinical Pipline
Product Overview
Nemonoxacin
Burixafor
TG-2349
Development Projects
Nemonoxacin
Burixafor
TG-2349
Research
Anti-influenza Drug
Anti-Gram Negative Bacteria Drug
News
Presentation
Price/Dividend
Price
Dividend information
Shareholders services
IPO Conference
Shareholders' Meeting
Investor Conference
Financial information
Financial Report
Monthly Sales
Material information
Corporate governance
Contacts
Location
Home
中文
- TaiGen Biotechnology Receives Marketing Approval from the Taiwan Food ...
(3/13/2014 )
- TaiGen Biotechnology IPO in Taiwan GreTai Securities Market
(1/17/2014 )
- TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm f...
(1/15/2014 )
- TaiGen Biotechnology Receives Qualified Infectious Disease Product and...
(12/23/2013 )
- TaiGen announces TG-2349 poster presented in the American Association ...
(11/5/2013 )
Nemonoxacin
Broad-spectrum Antibiotic
Burixafor
Novel Stem Cell Mobilizer
TG-2349
Hepatitis C Virus Protease Inhibitor
